Literature DB >> 28394257

Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.

Hiroshi Okuda, Boban Stanojevic, Akinori Kanai, Takeshi Kawamura, Satoshi Takahashi, Hirotaka Matsui, Akifumi Takaori-Kondo, Akihiko Yokoyama.   

Abstract

The eleven-nineteen leukemia (ENL) protein family, composed of ENL and AF9, is a common component of 3 transcriptional modulators: AF4-ENL-P-TEFb complex (AEP), DOT1L-AF10-ENL complex (referred to as the DOT1L complex) and polycomb-repressive complex 1 (PRC1). Each complex associates with chromatin via distinct mechanisms, conferring different transcriptional properties including activation, maintenance, and repression. The mixed-lineage leukemia (MLL) gene often fuses with ENL and AF10 family genes in leukemia. However, the functional interrelationship among those 3 complexes in leukemic transformation remains largely elusive. Here, we have shown that MLL-ENL and MLL-AF10 constitutively activate transcription by aberrantly inducing both AEP-dependent transcriptional activation and DOT1L-dependent transcriptional maintenance, mostly in the absence of PRC1, to fully transform hematopoietic progenitors. These results reveal a cooperative transcriptional activation mechanism of AEP and DOT1L and suggest a molecular rationale for the simultaneous inhibition of the MLL fusion-AF4 complex and DOT1L for more effective treatment of MLL-rearranged leukemia.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28394257      PMCID: PMC5409830          DOI: 10.1172/JCI91406

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription.

Authors:  Nanhai He; Min Liu; Joanne Hsu; Yuhua Xue; Seemay Chou; Alma Burlingame; Nevan J Krogan; Tom Alber; Qiang Zhou
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

2.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes.

Authors:  Akihiko Yokoyama; Michael L Cleary
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

3.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

4.  Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.

Authors:  Michael W M Kühn; Evelyn Song; Zhaohui Feng; Amit Sinha; Chun-Wei Chen; Aniruddha J Deshpande; Monica Cusan; Noushin Farnoud; Annalisa Mupo; Carolyn Grove; Richard Koche; James E Bradner; Elisa de Stanchina; George S Vassiliou; Takayuki Hoshii; Scott A Armstrong
Journal:  Cancer Discov       Date:  2016-08-17       Impact factor: 39.397

5.  AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation.

Authors:  Yuanyuan Li; Hong Wen; Yuanxin Xi; Kaori Tanaka; Haibo Wang; Danni Peng; Yongfeng Ren; Qihuang Jin; Sharon Y R Dent; Wei Li; Haitao Li; Xiaobing Shi
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

6.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

7.  Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.

Authors:  Qin Feng; Hengbin Wang; Huck Hui Ng; Hediye Erdjument-Bromage; Paul Tempst; Kevin Struhl; Yi Zhang
Journal:  Curr Biol       Date:  2002-06-25       Impact factor: 10.834

8.  Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias.

Authors:  D C Tkachuk; S Kohler; M L Cleary
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

9.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells.

Authors:  Tim C P Somervaille; Christina J Matheny; Gary J Spencer; Masayuki Iwasaki; John L Rinn; Daniela M Witten; Howard Y Chang; Sheila A Shurtleff; James R Downing; Michael L Cleary
Journal:  Cell Stem Cell       Date:  2009-02-06       Impact factor: 24.633

10.  Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties.

Authors:  Akihiko Yokoyama; Issay Kitabayashi; Paul M Ayton; Michael L Cleary; Misao Ohki
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

View more
  27 in total

Review 1.  ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.

Authors:  Jianbiao Zhou; Yvonne Ng; Wee-Joo Chng
Journal:  Cell Mol Life Sci       Date:  2018-07-31       Impact factor: 9.261

2.  BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC Activity.

Authors:  Charles R Schmidt; Nicholas J Achille; Aravinda Kuntimaddi; Adam M Boulton; Benjamin I Leach; Shubin Zhang; Nancy J Zeleznik-Le; John H Bushweller
Journal:  Blood Cancer Discov       Date:  2020-09

3.  Proteomic approaches for cancer epigenetics research.

Authors:  Dylan M Marchione; Benjamin A Garcia; John Wojcik
Journal:  Expert Rev Proteomics       Date:  2018-11-27       Impact factor: 3.940

Review 4.  Therapeutic targeting potential of chromatin-associated proteins in MLL-rearranged acute leukemia.

Authors:  Xin Xu; Björn Schneider
Journal:  Cell Oncol (Dordr)       Date:  2018-11-16       Impact factor: 6.730

5.  Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.

Authors:  Garrett S Gibbons; Amarraj Chakraborty; Sierrah M Grigsby; Afoma C Umeano; Chenzhong Liao; Omar Moukha-Chafiq; Vibha Pathak; Bini Mathew; Young-Tae Lee; Yali Dou; Stephan C Schürer; Robert C Reynolds; Timothy S Snowden; Zaneta Nikolovska-Coleska
Journal:  Eur J Med Chem       Date:  2020-01-02       Impact factor: 6.514

6.  A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.

Authors:  Andrei V Krivtsov; Kathryn Evans; Jayant Y Gadrey; Benjamin K Eschle; Charlie Hatton; Hannah J Uckelmann; Kenneth N Ross; Florian Perner; Sarah N Olsen; Tara Pritchard; Lisa McDermott; Connor D Jones; Duohui Jing; Ali Braytee; Diego Chacon; Eric Earley; Brian M McKeever; David Claremon; Andrew J Gifford; Heather J Lee; Beverly A Teicher; John E Pimanda; Dominik Beck; Jennifer A Perry; Malcolm A Smith; Gerard M McGeehan; Richard B Lock; Scott A Armstrong
Journal:  Cancer Cell       Date:  2019-12-09       Impact factor: 31.743

7.  Nuclear FGFR2 Interacts with the MLL-AF4 Oncogenic Chimera and Positively Regulates HOXA9 Gene Expression in t(4;11) Leukemia Cells.

Authors:  Tiziana Fioretti; Armando Cevenini; Mariateresa Zanobio; Maddalena Raia; Daniela Sarnataro; Fabio Cattaneo; Rosario Ammendola; Gabriella Esposito
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

Review 8.  Multifaceted roles of YEATS domain-containing proteins and novel links to neurological diseases.

Authors:  Ranchana Yeewa; Pawita Chaiya; Salinee Jantrapirom; Vorasuk Shotelersuk; Luca Lo Piccolo
Journal:  Cell Mol Life Sci       Date:  2022-03-12       Impact factor: 9.261

9.  Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.

Authors:  William F Richter; Rohan N Shah; Alexander J Ruthenburg
Journal:  Elife       Date:  2021-07-15       Impact factor: 8.140

Review 10.  The Intrinsically Disordered Proteins MLLT3 (AF9) and MLLT1 (ENL) - Multimodal Transcriptional Switches With Roles in Normal Hematopoiesis, MLL Fusion Leukemia, and Kidney Cancer.

Authors:  Ashish Kabra; John Bushweller
Journal:  J Mol Biol       Date:  2021-06-23       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.